Cargando…

Incremental value of mineralocorticoid receptor antagonists in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan

AIMS: We investigated the incremental advantage in terms of N-terminal pro-B-type natriuretic peptide (NT-proBNP) reduction in patients affected by heart failure with reduced ejection fraction (HFrEF) treated with sacubitril/valsartan (S/V) and mineralocorticoid receptor antagonists (MRA) versus pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Benini, Annachiara, Bingel, Anne, Neumann, Konrad, Edelmann, Frank, Schönrath, Felix, Pieske, Burkert, Messroghli, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Heart Failure and Cardiomyopathies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772686/ https://www.ncbi.nlm.nih.gov/pubmed/36543361 http://dx.doi.org/10.1136/openhrt-2022-002069

Ejemplares similares

Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study
por: Ganesananthan, Sashiananthan, et al.
Publicado: (2020)

PREDICTORS OF LIKELIHOOD OF TAKING SACUBITRIL-VALSARTAN AND A HYPOTHETICAL MEDICATION FOR COVID-19
por: Thomson, Mary Catherine, et al.
Publicado: (2021)

Beneficial and harmful effects of sacubitril/valsartan in patients with heart failure: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis
por: Nielsen, Emil Eik, et al.
Publicado: (2020)

Scar burden is an independent and incremental predictor of cardiac resynchronisation therapy response
por: Harb, Serge C, et al.
Publicado: (2019)

Incremental role of CT coronary angiography in the assessment of left ventricular diastolic function
por: Lange, Aleksandra, et al.
Publicado: (2021)

Prognostic impacts of changes in left ventricular ejection fraction in heart failure patients with preserved left ventricular ejection fraction
por: Yoshihisa, Akiomi, et al.
Publicado: (2020)

Ischaemia change with revascularisation versus medical therapy in reduced ejection fraction
por: Mentz, Robert J, et al.
Publicado: (2015)

Ethnic differences in the association of QRS duration with ejection fraction and outcome in heart failure
por: Gijsberts, Crystel M, et al.
Publicado: (2016)

Iron deficiency in heart failure with preserved ejection fraction: a systematic review and meta-analysis
por: Beale, Anna L, et al.
Publicado: (2019)

Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction
por: Salah, Khibar, et al.
Publicado: (2019)

Impact of atrial fibrillation in patients with heart failure and reduced, mid-range or preserved ejection fraction
por: Son, Mi Kyoung, et al.
Publicado: (2020)

Diastolic index as a short-term prognostic factor in heart failure with preserved ejection fraction
por: Hoshida, Shiro, et al.
Publicado: (2020)

Association of early versus delayed normalisation of left ventricular ejection fraction with mortality in ischemic cardiomyopathy
por: Schiffer, Walter B, et al.
Publicado: (2021)

Sacubitril/valsartan reduces cardiac decompensation in heart failure with preserved ejection fraction: a meta-analysis
por: Basile, Christian, et al.
Publicado: (2023)

Reporting trends of randomised controlled trials in heart failure with preserved ejection fraction: a systematic review
por: Zheng, Sean L, et al.
Publicado: (2016)

Mild aortic valve disease and the diastolic pressure–volume relationship in heart failure with preserved ejection fraction
por: Verbrugge, Frederik H, et al.
Publicado: (2021)

Copeptin in patients with heart failure and preserved ejection fraction: a report from the prospective KaRen-study
por: Hage, Camilla, et al.
Publicado: (2015)

Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis
por: Zheng, Sean Lee, et al.
Publicado: (2018)

Baseline characteristics of patients with heart failure and preserved ejection fraction at admission with acute heart failure in Saudi Arabia
por: Abohammar, Samah, et al.
Publicado: (2017)

Association between implanted cardioverter-defibrillators and mortality for patients with left ventricular ejection fraction between 30% and 35%
por: Wasfy, Jason H, et al.
Publicado: (2023)

Development of algorithms for determining heart failure with reduced and preserved ejection fraction using nationwide electronic healthcare records in the UK
por: Sundaram, Varun, et al.
Publicado: (2022)

Medications for specific phenotypes of heart failure with preserved ejection fraction classified by a machine learning-based clustering model
por: Sotomi, Yohei, et al.
Publicado: (2023)

Developing a contemporary community clinic for patients with heart failure with preserved ejection fraction within the current National Health Service model
por: Tran, Patrick, et al.
Publicado: (2022)

Extracellular cardiac matrix biomarkers in patients with reduced ejection fraction heart failure as predictors of response to cardiac resynchronisation therapy: a systematic review
por: McAloon, Christopher J, et al.
Publicado: (2017)

Non-invasive intraventricular pressure differences estimated with cardiac MRI in subjects without heart failure and with heart failure with reduced and preserved ejection fraction
por: Londono-Hoyos, Francisco, et al.
Publicado: (2019)

Prognostic value of left ventricular mitral annular longitudinal displacement obtained by tissue Doppler imaging in patients with heart failure with reduced ejection fraction
por: Sengeløv, Morten, et al.
Publicado: (2021)

Correction: Incremental value of mineralocorticoid receptor antagonists in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan
Publicado: (2023)

Rationale and design of the preserved versus reduced ejection fraction biomarker registry and precision medicine database for ambulatory patients with heart failure (PREFER-HF) study
por: Abboud, Andrew, et al.
Publicado: (2021)

Colchicine in patients with heart failure and preserved left ventricular ejection fraction: rationale and design of a prospective, randomised, open-label, crossover clinical trial
por: Shchendrygina, Anastasia, et al.
Publicado: (2023)

Comparative cardiovascular outcomes of novel drugs as an addition to conventional triple therapy for heart failure with reduced ejection fraction (HFrEF): a network meta-analysis of randomised controlled trials
por: Suebsaicharoen, Thanakit, et al.
Publicado: (2023)

Rationale and design of the NEO-NORMAL-AF study examination of the usefulness of implantable loop recorder for arrhythmia detection including atrial fibrillation in heart failure with non-reduced ejection fraction cases: a pilot study
por: Sugiura, Junichi, et al.
Publicado: (2023)

Sacubitril/valsartan versus angiotensin inhibitors and arrhythmia endpoints in heart failure with reduced ejection fraction
por: Fernandes, Amanda D.F., et al.
Publicado: (2021)

Cardiac resynchronisation therapy in paediatric and congenital heart disease: differential effects in various anatomical and functional substrates
por: Janoušek, J, et al.
Publicado: (2009)

Prospective development and validation of a model to predict heart failure hospitalisation
por: Cubbon, R M, et al.
Publicado: (2014)

Inflammation and echocardiographic parameters of ventricular hypertrophy in a cohort with preserved cardiac function
por: Medenwald, D, et al.
Publicado: (2014)

Endothelial function and left ventricular diastolic functional reserve in type 2 diabetes mellitus
por: Leung, Melissa, et al.
Publicado: (2014)

Trends in left ventricular assist device use and outcomes among Medicare beneficiaries, 2004–2011
por: Lampropulos, Julianna F, et al.
Publicado: (2014)

Vitamin D levels and left ventricular diastolic function
por: Pandit, Anil, et al.
Publicado: (2014)

Novel cardiac pacemaker-based human model of periodic breathing to develop real-time, pre-emptive technology for carbon dioxide stabilisation
por: Baruah, Resham, et al.
Publicado: (2014)

Functional, morphological and electrocardiographical abnormalities in patients with apical hypertrophic cardiomyopathy and apical aneurysm: correlation with cardiac MR
por: Suwa, Kenichiro, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_j92hl1s8r6tng584qdfgciv8id